Last update 21 Nov 2024

Live-attenuated measles/mumps vaccine(Wuhan Institute of Biological Products Co., Ltd.)

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Combination vaccine, Live attenuated vaccine, Prophylactic vaccine

Synonyms

Measles and Mumps Combined Vaccine, Live, 麻疹腮腺炎联合减毒活疫苗（武汉生物制品研究所）, Wu Sheng Si Lin

+ [1]

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesMouth and Tooth Diseases

Active Indication

MeaslesMumps

Inactive Indication-

Originator Organization

Wuhan Institute of Biological Products Co., Ltd.

Active Organization

Wuhan Institute of Biological Products Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (23 Apr 2003),

MeaslesMumps

Regulation-

100 Clinical Results associated with Live-attenuated measles/mumps vaccine(Wuhan Institute of Biological Products Co., Ltd.)

100 Translational Medicine associated with Live-attenuated measles/mumps vaccine(Wuhan Institute of Biological Products Co., Ltd.)

100 Patents (Medical) associated with Live-attenuated measles/mumps vaccine(Wuhan Institute of Biological Products Co., Ltd.)

Literatures (Medical) associated with Live-attenuated measles/mumps vaccine(Wuhan Institute of Biological Products Co., Ltd.)

01 Aug 2021·Neurology Clinical Practice

Uptake and Attitudes About Immunizations in People With Multiple Sclerosis

Article

Author: Cutter, Gary R. ; Marrie, Ruth Ann ; Salter, Amber ; Fox, Robert ; Kosowan, Leanne

ObjectiveBy surveying a multiple sclerosis (MS) population, we tested the hypothesis that influenza vaccine uptake would not meet public health targets and that vaccine misconceptions would contribute to lower than desired uptake.MethodsIn spring 2020, we surveyed participants in the North American Research Committee on Multiple Sclerosis Registry regarding vaccinations. Participants reported whether they had received hepatitis A, hepatitis B, pneumococcal, shingles, varicella, measles/mumps/rubella, tetanus, or influenza vaccines. Participants who had not received influenza vaccine last year reported the reasons. We summarized responses descriptively. Using multivariable logistic regression, we assessed participant characteristics associated with uptake of seasonal influenza vaccine.ResultsOf 5,244 eligible respondents, 80.8% were female, with a mean (SD) age of 61.8 (10.1) years. Overall, 43.0% (2,161/5,032) of participants reported that their neurologist had ever asked about their immunization history. The percentage of participants who received the seasonal flu vaccine last year ranged from 59.1% among those aged 18–24 years to 79.9% for persons aged ≥65 years. Among those who did not get the influenza vaccination, the most common reasons were personal preference (29.6%), concerns about possible adverse effects in general (29.3%), and concerns that the vaccine would worsen their MS (23.7%).ConclusionVaccination uptake is lower than desired in the MS population compared with existing recommendations, including for seasonal influenza. Misconceptions about the safety of vaccination in the context of MS and personal preference appear to play important roles in vaccination choices, highlighting the importance of education about these issues.

01 Aug 2018·VirologyQ3 · MEDICINE

Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model

Q3 · MEDICINE

Article

Author: Hanauer, Jan R H ; Prüfer, Steffen ; Fiedler, Anna H ; Bodmer, Bianca S ; Mühlebach, Michael D

Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) continue to occur, making it one of the WHO´s targets for accelerated vaccine development. One vaccine candidate is based on live-attenuated measles virus (MV) vaccine encoding the MERS-CoV spike glycoprotein (MERS-S). MV_vac2-MERS-S(H) induces robust humoral and cellular immunity against MERS-S mediating protection. Here, the induction and nature of immunity after vaccination with MV_vac2-MERS-S(H) or novel MV_vac2-MERS-N were further characterized. We focused on the necessity for vector replication and the nature of induced T cells, since functional CD8⁺ T cells contribute importantly to clearance of MERS-CoV. While no immunity against MERS-CoV or MV was detected in MV-susceptible mice after immunization with UV-inactivated virus, replication-competent MV_vac2-MERS-S(H) triggered robust neutralizing antibody titers also in adult mice. Furthermore, a significant fraction of MERS CoV-specific CD8⁺ T cells and MV-specific CD4⁺ T cells simultaneously expressing IFN-γ and TNF-α were induced, revealing that MV_vac2-MERS-S(H) induces multifunctional cellular immunity.

01 May 2012·Cancer LettersQ1 · MEDICINE

Live-attenuated measles virus vaccine confers cell contact loss and apoptosis of ovarian cancer cells via ROS-induced silencing of E-cadherin by methylation

Q1 · MEDICINE

Article

Author: Zhou, Shengtao ; Bian, Ce ; Huang, Fuqiang ; Huang, Canhua ; Li, Zhengyu ; Lin, Xiaojuan ; Zhang, Boya ; He, Xiang ; Zhao, Xia ; Luo, Hong ; Li, Yuhua ; Yi, Tao ; Liu, Ping ; Qi, Xiaorong ; Wei, Yuquan ; Zhong, Qian

Herein we present a novel molecular mechanism of the antitumor effects of live-attenuated measles virus (MV) vaccine in ovarian cancer. Using a 2-DE/MS-based comparative proteomics strategy, we identified 17 proteins differentially expressed in live-attenuated MV vaccine-treated SKOV-3 ovarian cancer cells, including oxidative stress-associated enzymes and cell contact-related proteins, which indicated that live-attenuated MV vaccine could induce aberrant ROS activation. It further mediated epigenetic silencing of E-cadherin via upregulating DNMT3a that conferred both cell-cell and cell-matrix contact loss and apoptosis of ovarian cancer cells. This process could be reversed through ROS inhibition. Our study lays the theoretical foundation for the clinical application of live-attenuated MV vaccine as a potential oncotherapeutic agent for ovarian cancer treatment.

100 Deals associated with Live-attenuated measles/mumps vaccine(Wuhan Institute of Biological Products Co., Ltd.)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BD51	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Measles	CN	Wuhan Institute of Biological Products Co., Ltd.	23 Apr 2003
Mumps	CN	Wuhan Institute of Biological Products Co., Ltd.	23 Apr 2003

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Live-attenuated measles/mumps vaccine(Wuhan Institute of Biological Products Co., Ltd.)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation